DEVELOPING FIRST IN CLASS ANTI-INFECTIVES USING OUT LYSIN PLATFORM AND MONOCLOCAL ANTIBODIES.

ContraFect lab
ContraFect scientists are actively developing new ways to combat infectious diseases.

Lysins
Lysins are enzymes that digest the cell wall of bacteria. Once the cell wall is breached, the bacteria lyses in a virtually explosive manner. We believe lysins are unlike standard-of-care antibiotics, especially regarding their mechanism and speed of action. Traditional antibiotics, and most cytotoxic agents, require bacterial cell division and metabolism to occur in order to exert their effect (i.e., cell death or cessation of growth). Based on in vitro tests, lysins, however, are fundamentally different in that they rapid bactericidal activity. Lysins have the ability to kill bacteria immediately upon contact.
Read more...

Monoclonal Antibodies
Monoclonal antibodies are a well-established therapeutic modality for the treatment of cancers and immune-based disorders. While many of the World's biggest drugs are monoclonal antibodies, their use for the treatment of infectious disease has been limited due to the high mutation rates of bacteria and viruses. ContraFect scientists have overcome that challenge, and we are now exploring the use of antibodies for the treatment of life-threatening infectious diseases, such as influenza.
Read more...